Matthew H. Taylor
0000-0003-2409-9001
Publication & Citation Trends
Publications
0 total
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Cited by 0
Semantic Scholar
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Cited by 2
Semantic Scholar
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
Cited by 2
Semantic Scholar
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy OA
Cited by 8
Semantic Scholar
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation OA
Cited by 14
Semantic Scholar
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib OA
Cited by 16
Semantic Scholar
Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers
Cited by 0
Semantic Scholar
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting OA
Cited by 4
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(78)
Melanoma and MAPK Pathways
(50)
Lung Cancer Treatments and Mutations
(37)
CAR-T cell therapy research
(37)
Thyroid Cancer Diagnosis and Treatment
(36)
Affiliations
Brigham Young University
Pennsylvania State University
Memorial Sloan Kettering Cancer Center
University of the West Indies System
Oregon Health & Science University